Tag:
XL880
Latest Headlines
Latest Headlines
Glaxo leaves Exelixis drugs behind as pact ends
Exelixis' six-year collaboration with GlaxoSmithKline has come to the end of the line with Glaxo deciding to bow out without licensing any of the drugs in the program. Exelixis retains the rights
Cancer therapy gets accelerated review at Exelixis
Exelixis and GlaxoSmithKline say they're hitting the gas on their program to develop XL880 as a "leading" MET inhibitor for cancer. Exelixis will review the therapy before
